RIGEL PHARMACEUTICALS INC
RIGL evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for RIGL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RIGL
Rigel Pharmaceuticals is a commercial-stage biotechnology company focused on developing and commercializing small-molecule drugs for hematologic disorders and cancer, with marketed products TAVALISSE, REZLIDHIA, and GAVRETO.
Key risk: Regulatory adverse decisions
BioSniper Score
Based on 6 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 5 pipeline candidates · 4 clinical trials · 3 catalysts · 4 FDA decisions for RIGEL PHARMACEUTICALS INC.
Rigel Pharmaceuticals is a commercial-stage biotechnology company focused on developing and commercializing small-molecule drugs for hematologic disorders and cancer, with marketed products TAVALISSE, REZLIDHIA, and GAVRETO.
- Rigel has three FDA-approved products: TAVALISSE (fostamatinib) for chronic immune thrombocytopenia, REZLIDHIA (olutasidenib) for IDH1-mutant acute myeloid leukemia, and GAVRETO (pralsetinib) for RET-altered cancers [sec_mda · as of 2026-08-04].
- As of 2026-06-30, Rigel reported total revenue of $78.7M, net income of $17.3M, cash & equivalents of $60.9M, shareholders' equity of $391.5M, and total debt of $40.0M [sec].
- The company maintains expertise in kinase inhibition, specifically SYK, IRAK1/4, and RIPK1 kinases, and in mIDH1, to support clinical development and explore new opportunities [sec_mda · as of 2025-08-05].
- Rigel believes its existing capital resources will support projected funding requirements, including continued product commercialization, through at least the next 12 months from its most recent filing [sec_mda · as of 2026-03-03].
What works
- Rigel has three approved products generating revenue, providing a commercial foundation and multiple sources of income [sec_mda · as of 2026-08-04].
- The company reported positive net income of $17.3M as of 2026-06-30, indicating a shift toward profitability [sec].
- Rigel's deep expertise in kinase inhibition (SYK, IRAK1/4, RIPK1) and mIDH1 provides a strong platform for pipeline expansion [sec_mda · as of 2025-08-05].
What to weigh
- Rigel faces risks from regulatory authorities (FDA, EMA, MHRA) that could make adverse decisions affecting product approvals or commercialization [sec_mda · as of 2026-08-04].
- The company's future funding requirements depend on uncertain factors such as product revenue generation and clinical trial costs, which could strain capital if expectations are not met [sec_mda · as of 2026-05-05].
- Raising additional funds through collaboration or licensing may require Rigel to relinquish rights to technologies or product candidates on unfavorable terms [sec_mda · as of 2026-05-05].
From the filings
Quoted directly from source documents.
Rigel has three marketed products: TAVALISSE, REZLIDHIA, and GAVRETO.
“risks and uncertainties associated with the commercialization, distribution, marketing, and payment for our products in the US and outside the US”
SEC MD&A · August 4, 2026
Rigel maintains expertise in SYK, IRAK1/4, RIPK1 kinases and mIDH1.
“We also maintain leading expertise on specific areas of operation such as inhibition of SYK, IRAK 1/4 and RIPK1 kinases and mIDH1 to assist clinical development and commercial affairs”
SEC MD&A · August 5, 2025
Rigel believes existing capital resources will fund operations for at least 12 months from the filing date.
“We believe that our existing capital resources will be sufficient to support our current and projected funding requirements, including the continued commercialization of our products, through at least the next 12 months from this Form 10-K filing date.”
SEC MD&A · March 3, 2026
Catalyst timeline
- 2032-07-27 · Patent_Expiry · TAVALISSE — Patent/exclusivity expiry for TAVALISSE, which could open the market to generic competition.
- 2039-11-12 · Patent_Expiry · REZLIDHIA — Patent/exclusivity expiry for REZLIDHIA, potentially affecting long-term revenue exclusivity.
- 2042-07-07 · Patent_Expiry · GAVRETO — Patent/exclusivity expiry for GAVRETO, marking a distant but eventual loss of market exclusivity.
Risks & what to watch (3)›
Key risks
- Regulatory adverse decisions — FDA, EMA, or MHRA may make adverse decisions regarding Rigel's products, impacting commercialization [sec_mda · as of 2026-08-04].
- Dependence on product revenue — Future funding depends on product revenue generation, which is uncertain and could lead to capital shortfalls [sec_mda · as of 2026-05-05].
- Unfavorable licensing terms — Raising funds via collaborations may require relinquishing rights to technologies or product candidates on unfavorable terms [sec_mda · as of 2026-05-05].
What to watch
- Revenue trends from TAVALISSE, REZLIDHIA, and GAVRETO, as they are key to sustaining profitability [sec].
- Regulatory decisions from FDA, EMA, or MHRA that could affect product approvals or market access [sec_mda · as of 2026-08-04].
- Progress of preclinical and clinical programs in kinase inhibition and mIDH1, which may expand the pipeline [sec_mda · as of 2025-08-05].
- Cash runway updates, as Rigel's capital resources are estimated to last at least 12 months from the latest filing [sec_mda · as of 2026-03-03].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run RIGEL PHARMACEUTICALS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available RIGEL PHARMACEUTICALS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
Profitable (positive operating cash flow)
D/E 0.22 · 6% dilution
Lead: Approved
5 candidates
3 upcoming, next in ~2158d
0 buys · 2 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
148
Total value held
$423.0M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 1,768,907 | $47.8M |
| vanguard capital management llc | 1,528,386 | $41.3M |
| armistice capital, llc | 1,280,000 | $34.6M |
| state street corp | 1,120,238 | $30.3M |
| marshall wace, llp | 598,378 | $16.2M |
| american century companies inc | 544,431 | $14.7M |
| d. e. shaw & co., inc. | 445,678 | $12.1M |
| geode capital management, llc | 440,626 | $11.9M |
| goldman sachs group inc | 439,101 | $11.9M |
| two sigma investments, lp | 405,807 | $11.0M |
Showing top 10 of 148 institutional holders of RIGEL PHARMACEUTICALS INC. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 21.8%
- Days to cover
- 11.6
- Shares short
- 3,935,324
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
RIGL short interestGovernance
Frequently asked questions
What is the AI investment thesis for RIGEL PHARMACEUTICALS INC?
Rigel Pharmaceuticals is a commercial-stage biotechnology company focused on developing and commercializing small-molecule drugs for hematologic disorders and cancer, with marketed products TAVALISSE, REZLIDHIA, and GAVRETO.
What is RIGEL PHARMACEUTICALS INC's lead drug candidate?
RIGEL PHARMACEUTICALS INC's most advanced tracked candidate is gavreto (Approved) for metastatic RET fusion-positive non-small cell lung cancer (NSCLC) and advanced or metastatic RET fusion-positive thyroid cancer.
What is RIGEL PHARMACEUTICALS INC's next catalyst?
RIGEL PHARMACEUTICALS INC's next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: TAVALISSE" — expected July 27, 2032.
Who is the CEO of RIGEL PHARMACEUTICALS INC?
Mr. Raul R. Rodriguez is the chief executive officer of RIGEL PHARMACEUTICALS INC (RIGL).
Where is RIGEL PHARMACEUTICALS INC headquartered?
RIGEL PHARMACEUTICALS INC (RIGL) is headquartered in South San Francisco, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.